You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 1
  • LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study

Article metrics

Article menu

Download PDFPDF

Short Oral Presentation
Short oral presentation session 3: SLE biomarkers 1
LSO-015 Deucravacitinib reduces interferons, B cell pathways, and serological biomarkers of systemic lupus disease activity: pharmacodynamic analysis from the phase 2 PAISLEY study

 

Online download statistics by month:

Online download statistics by month: August 2023 to August 2024

AbstractFullPdf
Aug 20235007
Sep 20231405
Oct 20232104
Nov 20234107
Dec 20231201
Jan 20245201
Feb 20244006
Mar 202443011
Apr 20245404
May 20242402
Jun 20244105
Jul 20243506
Aug 20241803
Total445062